Jon Wigginton MD Receives SITC Visionary Legacy Award


CAMBRIDGE, Mass.– Cullinan Oncology is proud to announce that its Chief Medical Officer, Jon Wigginton MD, has been honored by the Society for Immunotherapy of Cancer (SITC) as a recipient of its 2020 Visionary Legacy Award.

This nominated award honors SITC members who are visionaries in the field of cancer immunotherapy and continue to show extraordinary ingenuity with continuous contributions in support of improving cancer patient outcomes.

“Jon has dedicated his life to improving the lives of those living with cancer, and this award recognizes his many contributions to the Society and the broader field of cancer immunotherapy. We are fortunate to have his knowledge, expertise and leadership at Cullinan as we work to develop the next breakthroughs for patients,” said Owen Hughes, CEO at Cullinan Oncology.

In addition to his role as the Chief Medical Officer at Cullinan, Jon is also an advisor at MPM Capital, a leading venture capital firm located in Cambridge, MA and several biotechnology companies. Jon served previously as President of the Society for Immunotherapy of Cancer, and he led multiple SITC programmatic initiatives.